Back to Results
First PageMeta Content
Sexually transmitted diseases and infections / Biology / Antiviral drug / HIV / Viral load / Antiretroviral drug / Virus / Hepatitis B / AIDS / HIV/AIDS / Medicine / Health


ADVERTISEMENT FEATURE ABIVAX www.abivax.c om Breaking new ground in anti-infectives
Add to Reading List

Document Date: 2015-04-06 11:46:53

Open Document

File Size: 166,15 KB

Share Result on Facebook

City

Montpellier / Paris / /

Company

N B26 / ABIVAX / National Center / CIGB / Truffle Capital / /

Continent

Asia / Africa / /

Country

Cuba / France / /

/

Event

Business Partnership / FDA Phase / /

Facility

Finlay Institute / ABIVAX’s pipeline / /

IndustryTerm

biopharmaceutical / biotechnology / late-stage products / chemical library / technology platforms / in-house biotechnology expertise / product manufacturing / /

MedicalCondition

HIV infection / leptospirosis / chronic hepatitis B. The / HIV / disease / HBV / hepatitis B / viral diseases / typhoid / meningococcal disease / tant viral infections / recombinant hepatitis B / infectious diseases / chronic hepatitis B / /

MedicalTreatment

antiviral therapies / highly active antiretroviral therapy / HAART / /

Organization

Finlay Institute / Institut Curie / Cuban Center for Genetic Engineering and Biotechnology / International AIDS Society / /

Person

Philippe Pouletty / Hartmut J. Ehrlich / Karl Birthistle / /

/

Position

managing partner / CEO / VP Global Regulatory Affairs ABIVAX Paris / chair / /

Product

ABX203 / ABX464 / /

Region

Latin America / /

Technology

Genetic Engineering / biotechnology / anti-infectives / /

URL

www.nature.com/biopharmadealmakers / www.abivax.c / /

SocialTag